Two new studies from Rady Childrens Institute for Genomic Medicine (RCIGM) find that parents and doctors of critically ill infants view first line sequencing as beneficial, whether or not a definitive diagnosis is achieved. The studies were both part of the second Newborn Sequencing in Genomic Medicine and Public Health (NSIGHT2) study and were published in early November in The American Journal of Human Genetics.

This groundbreaking research into stakeholders experiences with sequencing in the NICU provides another justification for incorporating sequencing as standard care of critically ill infants with undiagnosed conditions. RCIGM is one of the worlds leading centers for rapid genomic sequencing of infants and children with serious undiagnosed diseases.

(Thousands of) conditions can be diagnosed using sequencing, says David Dimmock, M.D., senior medical director for RCIGM, lead author of one paper, and a contributing author on the other. However, there has been little research into how parents and clinicians of infants who have undergone sequencing view the process. The results, say the Rady researchers, were surprisingly positive.

The sequencing part of the study used the Illumina Novoseq 6000 and both whole-exome sequencing (WES) and whole-genome sequencing (WGS) were used. Results were confirmed using Sanger sequencing, chromosomal microarrays, or other methods, and were typically returned, on average, in 12 days. A total of 213 infants were enrolled, but those considered very ill were tested and excluded from the study.

In the case of babies who received genomic sequencing, we surveyed their physicians and parents and found that both groups overwhelmingly felt that genetic testing was beneficial, says Stephen Kingsmore, M.D., DSc, president & CEO of RCIGM. When results are positive, sequencing reveals the genetic variation responsible for the childs disease. But what astounded us was the high proportion of both doctors and parents who perceived that this testing had life-changing utility, even in cases when results were negative for genetic disease.

All of the cases for these two studies were from Radys own ICU, although the NSIGHT project encompasses other sites as well. This study included 201 infants who received rapid genomic sequencing. The physicians found genomic sequencing medically useful 93% (42 of 45 cases) of the time when the test was positiveor helped to make a diagnosis. When the test was negative, sequencing was also deemed useful 72% (112 of 156) of the time. According to the physicians, rapid genomic sequencing improved outcomes for 32 infants in the study. Changes in the patients management were more likely when test results were returned rapidly.

Parents also had an overwhelmingly positive view of genomic testing in the ICU setting. Of 161 parents whose children received sequencing, 97% reported that the testing was useful. Only two parents reported that testing increased their stress or confusion. Overall, in 81% of the cases, families and their clinicians agreed that genomic test results were useful. Besides seeing the testing as beneficial, parents were mostly satisfied with the process. The authors of the paper on parents responses wrote, Most parents in this study perceived being adequately informed to consent, understood their childs results, and denied regret or harm from undergoing sequencing.

As part of the study, Findings that explained the hospitalization were always returned, notes Dimmock, and actionable off-target findings were also returned if requested.

Not surprisingly, positive results were viewed as more useful and beneficial than negative results. But families who did not get positive results were eligible for follow-up that might include additional sequencing if warranted.

These studies clearly show that genomic sequencing can be done safely in the NICU, leading to improved communication between families and their healthcare teams, says Dimmock. These results underscore the importance of rapid test results in changing care.

The patients clinicians, typically a neonatologist or pediatric intensivist, were the ones who reported test results to the parents. Dimmock noted that at the start of the study, some physicians who were not specialists in genetics reported anxiety about whether they would be able to do this. This concern was later discussed with many of the othersites in the overall study as well.

Rady has been pioneering the use of rapid diagnostic sequencing in pediatric ICUs. In apilotstudy funded by theState of California, their teamdemonstrated that a rapid sequencing of critically illbabies enrolled in Medi-Cal produced better health outcomes and reduced suffering for the infants while decreasing the cost of their care. The study, named ProjectBaby Bear,helpeddoctors identifythe exact cause of rare, genetic diseasesin an average of three days, instead of the four to six weeks required for standard genetic testing.

The hospital has also published research in Genomic Medicine (2018) showing that whole-genome sequencing and whole-exome sequencing of children with suspected genetic diseases are more useful for establishing a diagnosis than chromosomal microarrays (CMAs), which are the traditional testing method for such cases.

Other stakeholders seem to be watching the progress of programs like Radys as well. In March of this year, Blue Shield of California became the first health plan in the United States to cover rapid and ultra-rapid Whole Genome Sequencing for critically ill babies and children in intensive care with unexplained medical conditions.

The biggest barriers to this type of testing becoming widespread, Dimmock adds, is getting institutional approval for the procedure and reimbursement. The Rady researchers will be looking at their data further with respect to costs to help address that latter challenge.

The rest is here:
First Line Sequencing Seen as a Win for Both Parents and Doctors of Infants in ICU - Clinical OMICs News

Recommendation and review posted by Bethany Smith

The recent published research report sheds light on critical aspects of the global Breast Cancer Predictive Genetic Testing market such as vendor landscape, competitive strategies, market drivers and challenges along with the regional analysis. The report helps the readers to draw a suitable conclusion and clearly understand the current (Ongoing COVID-19) and future scenario and trends of global Breast Cancer Predictive Genetic Testing market. The research study comes out as a compilation of useful guidelines for players to understand and define their strategies more efficiently in order to keep themselves ahead of their competitors. The report profiles leading companies of the global Breast Cancer Predictive Genetic Testing market along with the emerging new ventures who are creating an impact on the global market with their latest innovations and technologies.

The report consists of trends that are anticipated to impact the growth of the Breast Cancer Predictive Genetic Testing market during the forecast period between 2020 and 2026. Evaluation of these trends is included in the report, along with their product innovations.

Ask For Free Sample Copy of This Research Report:https://www.readmarketresearch.com/sample-request/33675-world-breast-cancer-predictive-genetic-testing-market

This Report covers the manufacturers data including shipment, price, revenue, gross profit, interview record, business distribution etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size and volume.

Global Breast Cancer Predictive Genetic Testing Market by Companies:Key companies listed in the report are:Roche, Thermo Fisher Scientific, PerkinElmer, Quest Diagnostics, Myriad Genetics, Iverson Genetics, Cancer Genetics, OncoCyte Corporation, NeoGenomics, Invitae

Global Breast Cancer Predictive Genetic Testing Market by Product:The key segment by type in the report includesHigh Penetrant Genes, Intermediate Penetrant Genes, Low Penetrant Genes

Global Breast Cancer Predictive Genetic Testing Market by Application:The report provides both market size and share information for following application from 2016-2026. The key applications of the market are:Hospitals, Clinics and Others

Read detail report:https://www.readmarketresearch.com/industry-report/33675/world-breast-cancer-predictive-genetic-testing-market

Table of ContentsGlobal Breast Cancer Predictive Genetic Testing Market Research Report 2020-2026, by Manufacturers, Regions, Types and Applications

1 Breast Cancer Predictive Genetic Testing Market Overview1.1 Introduction1.2 Scope1.3 Assumptions1.4 Players Covered1.5 Market Analysis By Type1.5.1 Global Breast Cancer Predictive Genetic Testing Market Size Growth Rate By Type (2020-2026)1.5.2 1.6 Market By Application1.6.1 Global Breast Cancer Predictive Genetic Testing Market Share By Application (2020-2026)1.6.2 Application I1.6.3 Application Ii1.6.4 1.7 Study Objectives1.8 Years

2 Executive Summary

3 Breast Cancer Predictive Genetic Testing Market Analysis by Type (Historic 2016-2026)3.1 Global Breast Cancer Predictive Genetic Testing Market Size Analysis (USD Million) 2016-20263.1.1 Type I3.1.2 Type Ii3.1.3 Type Iii3.2 Global Breast Cancer Predictive Genetic Testing Market Share Analysis by Type (%) 2016-2026

4 Breast Cancer Predictive Genetic Testing Market Analysis By Application (Historic 2016-2026)4.1 Global Breast Cancer Predictive Genetic Testing Market Size Analysis (USD Million) 2016-2026

5 Breast Cancer Predictive Genetic Testing Market Analysis By Regions (Historic 2016-2026)5.1 Global Breast Cancer Predictive Genetic Testing Market Size Analysis (USD Million) 2016-20265.1.1 Breast Cancer Predictive Genetic Testing Market Share By Regions (2016-2026)5.1.2 United States5.1.3 Europe5.1.4 China5.1.5 Japan5.1.6 India5.1.7 Rest Of The World

6 Key Companies Analysis/Company Profile

Continued..

Buy the Up-to-date Full Report @www.readmarketresearch.com/checkout?buynow=33675-world-breast-cancer-predictive-genetic-testing-market

Objectives of global Breast Cancer Predictive Genetic Testing Market Study: To define, describe, and analyse the global Breast Cancer Predictive Genetic Testing market based on product type, Application, and Region To forecast and analyse global Breast Cancer Predictive Genetic Testing market size (in terms of value and volume) and submarkets in 5 regions namely, APAC, Europe, North America, Central & South America, and the Middle East & Africa To forecast and analyse global Breast Cancer Predictive Genetic Testing market at country-level for each region To strategically analyse each submarket with respect to individual growth trends and their contribution to the global Breast Cancer Predictive Genetic Testing market To analyse opportunities in the market for stakeholders by identifying high growth segments of the global Breast Cancer Predictive Genetic Testing market To identify trends and factors driving or inhibiting the growth of the market and submarkets To analyse competitive developments, such as expansions and new product launches, in the global Breast Cancer Predictive Genetic Testing market To strategically profile key market players and comprehensively analyze their growth strategies

Ask for the discount:https://www.readmarketresearch.com/enquiry-before-purchase/33675-world-breast-cancer-predictive-genetic-testing-market*Get Upto $1000 Flat Discount on All License Type.

About UsWe at Read offers wide range of business services including but not limited to Market Research, Syndicate and Custom Research, Company Research, Business Consulting, Audit & Risk, Communications, Finance, Information Technology, Legal & Compliance, Human Resources and Sales.

Contact:Read Market ResearchDev Dixit (Sales Manager)B-51 CMPDI, Korba, ChhattisgarhPhone: +1 646 583 1932Email:[emailprotected]Web:https://www.readmarketresearch.comFollow Us on:LinkedIN

Read the original here:
Breast Cancer Predictive Genetic Testing Market 2026 Industry Trends, Size, Growth Insight, Share, Emerging Technologies, Share, Competitive,...

Recommendation and review posted by Bethany Smith

Syndicate Market Research published a new 110+ pages industry research, Industry Perspective, Comprehensive Analysis, and Forecast, 20202026in its database that focuses onGenetic Testing Services Marketand delivers in-depth market analysis and future prospects of Global Genetic Testing Services Market. This market report delivers the clean elaborated structure of the Genetic Testing Services Market comprising each and every business-related information of the market at a global level. The complete range of information related to the global Genetic Testing Services Market is obtained through various sources and this obtained bulk of the information is arranged, processed, and represented by a group of specialists through the application of different methodological techniques and analytical tools such as SWOT analysis to generate a whole set of trade-based study regarding the global Genetic Testing Services Market.

Request Sample is Available Genetic Testing Services Market Report @https://www.syndicatemarketresearch.com/sample/genetic-testing-services-market.html

The global Genetic Testing Services Market supports market-linked various associations, industries, vendors, firms, and organizations by offering a broad stage revealing opportunities time-to-time to rise higher in the market. Some of the chief contenders including pre-established businesses and newly-emerging firms are contending with one another for global trade expansion in terms of production, supply, demand, income, and after-sales services.

The Major Market Players Are:Hoffmann-La Roche Ltd, Illumina, 23andMe, Ambry Genetics, Genomic Health, Eurofins Scientific, LabCorp, CENTOGENE, Quest Diagnostics Incorporated, NeoGenomics Laboratories

Promising Regions & Countries Mentioned In The Genetic Testing Services Market Report:

North America (United States, Canada) Europe (UK, Germany, France) Asia-Pacific (Japan, China, India) Latin America (Argentina, Brazil) The Middle East & Africa

By the product type, the market is primarily split intoPredictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Others

By the application/end users, this report covers the following segmentsLarge National Laboratories, Small Laboratories, Specialty Laboratories, Diagnostic Laboratories, Others

The global Genetic Testing Services Market report presents the detailed extensive study regarding the market in an efficient way by dividing the whole market into different segments [Product, Applications, End-Users, and Major Regions] on the basis of type and form of product offered by the industries, product processing methods and techniques, end-user applications, and others. Not only this, but the market study also categorizes the market based on the regions [Latin America, North America, Asia Pacific, Middle & East Africa, and Europe]. The report also comprises the market growth forecast information calculated by the professional on the basis of previous information about the market and its related industries as well as the current trends followed by the market. The report also provides the markets CAGR forecast for the specific period of the upcoming time.

The report also highlights the various key factors as well as administrative guidelines that may impact the market in both ways, either direct or indirect. The global Genetic Testing Services Market report is embedded with several charts, figures, graphs, and diagrams to make it better understandable for the clients.

Following are significant Table of Content of Genetic Testing Services Market Report:

Industry Overview of Genetic Testing Services Market. Manufacturing Cost Structure Analysis of Genetic Testing Services Market market. Technical Data and Manufacturing Plants Analysis of Genetic Testing Services Market. Capacity, Production, and Revenue Analysis. Price, Cost, Gross, and Gross Margin Analysis of Genetic Testing Services Market by Regions, Types, and Manufacturers. Consumption Volume, Consumption Value, and Sale Price Analysis of Genetic Testing Services Market industry by Regions, Types, and Applications. Supply, Import, Export, and Consumption Analysis of Genetic Testing Services Market Market. Major Manufacturers Analysis of Genetic Testing Services Market industry. Marketing Trader or Distributor Analysis of Genetic Testing Services Market. Industry Chain Analysis of Genetic Testing Services Market. Development Trend Analysis of Genetic Testing Services Market Market. New Project Investment Feasibility Analysis of Genetic Testing Services Market. A conclusion of the Genetic Testing Services Market Industry.

Inquire more about this report @https://www.syndicatemarketresearch.com/inquiry/genetic-testing-services-market

Purposes Behind Buying Genetic Testing Services Market Report:-

This report gives stick direct investigation toward changing focused elements. It gives a forward-looking viewpoint on changed elements producing or restricting market development. It gives a five-year assessment surveyed based on how the market is anticipated to develop. It helps in understanding the essential part sections and their prospect. It gives stick point investigation of changing rivalry elements and keeps you in front of contenders. It helps in settling on educated business choices by having complete bits of knowledge of the market and by making a top to bottom investigation of market fragments.

Thanks for reading this article; you can also get individual chapter wise section or region wise report versions like North America, Europe, or Asia.

Contact Us:Email ID:[emailprotected]

Continued here:
Genetic Testing Services Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Zenit News

Recommendation and review posted by Bethany Smith

This report studies the Newborn and Prenatal Genetic Testing to get Covid-19 marketplace with Many details of the industry such as the market size, market standing, marketplace trends and prediction, the report also provides brief advice of their opponents as well as the particular growth opportunities with key market drivers. Locate the complete Newborn and Prenatal Genetic Testing to get Covid-19 market evaluation segmented by firms, area, type and software in the document.

New sellers from the marketplace are facing tough competition from Established foreign vendors as they fight with technological inventions, quality and reliability problems. The report will answer questions regarding the present market changes and the reach of competition, opportunity cost and much more.

Request Sample Report @ https://beathanreports.com/request-for-sample-report/7533

The report discusses the various Kinds of options for While the areas considered in the range of the report include North America, Europe, and assorted others. The analysis also highlights on how climbing digital security dangers is altering the industry situation.

Development policies and strategies are discussed along with Manufacturing processes and cost structures will also be examined. This report also claims import/export consumption, supply and demand Statistics, price, cost, earnings and gross earnings.

This report concentrates on the international Newborn and Prenatal Genetic Testing for Covid-19 Status, future prediction, growth opportunity, key marketplace and players.

The following players are covered in this report:

Perkin Elmer

Verinata Health

Sequenom, Inc.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

Natera, Inc.

Illumina, Inc.

Ariosa Diagnostics

BGI

CapitalBio MedLab

The Newborn and Prenatal Genetic Testing for Covid-19 marketplace is a comprehensive record Which supplies a meticulous summary of the market share, size, trends, demand, product evaluation, program analysis, regional perspective, competitive strategies, predictions, and strategies affecting the Newborn and Prenatal Genetic Testing for Covid-19 Industry. The report contains a thorough analysis of this marketplace competitive landscape, with the assistance of comprehensive business profiles, SWOT analysis, project feasibility analysis, and a lot of other specifics about the essential companies working on the marketplace.

Request Discount About This Report @ https://beathanreports.com/discount-request-on-report/7533

The analysis aims Covid-19 in global sector.

Breakdown Data by Type

PCR

FISH

aCGH

NIPT

MSS

Newborn and Prenatal Genetic Testing Breakdown Data by Application

Hospital

Clinic

Others

Based on regional and country-level analysis, the Newborn and Prenatal Genetic Testing market has been segmented as follows:

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Nordic

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia-Pacific

Latin America

Mexico

Brazil

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Newborn and Prenatal Genetic Testing market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.

The following players are covered in this report:

Perkin Elmer

Verinata Health

Sequenom, Inc.

Agilent Technologies, Inc.

Bio-Rad Laboratories, Inc.

Natera, Inc.

Illumina, Inc.

Ariosa Diagnostics

BGI

CapitalBio MedLab

The Newborn and Prenatal Genetic Testing for Covid-19 market study report entirely Covers the very important data of their capacity, manufacturing, value, cost/profit, supply/demand import/export, further separated by country and company, and from application/type for the best possible upgraded information representation from the statistics, tables, pie graph, and charts. These data representations give predictive information concerning the potential estimations for persuasive market development. The detailed and in depth understanding concerning our publishers makes us from the box in the event of market evaluation.

Key questions Answered within this report

Request For Customization About This Report @ https://beathanreports.com/request-for-customization/7533

Table of Contents

Chapter 1: Global Newborn and Prenatal Genetic Testing for Covid-19 Market Overview

Chapter 2: Newborn and Prenatal Genetic Testing for Covid-19 Market Data Analysis

Chapter 3: Newborn and Prenatal Genetic Testing for Covid-19 Technical Data Analysis

Chapter 4: Newborn and Prenatal Genetic Testing for Covid-19 Government Policy and News

Chapter 5: Global Newborn and Prenatal Genetic Testing for Covid-19 Market Manufacturing Process and Cost Structure

Chapter 6: Newborn and Prenatal Genetic Testing for Covid-19 Productions Supply Sales Demand Market Status and Forecast

Chapter 7: Newborn and Prenatal Genetic Testing for Covid-19 Key Manufacturers

Chapter 8: Up and Down Stream Industry Analysis

Chapter 9: Marketing Strategy -Newborn and Prenatal Genetic Testing for Covid-19 Analysis

Chapter 10: Newborn and Prenatal Genetic Testing for Covid-19 Development Trend Analysis

Chapter 11: Global Newborn and Prenatal Genetic Testing for Covid-19 Market New Project Investment Feasibility Analysis

Contact Us

Beathan Report,

4004 W Lake Sammamish,

Pkway B9 Redmond,

WA 98052 United States.

Tel: +44 115 888 3028

Web: http://www.beathanreports.com

About Us

At Beathan Report, we understand that the research we provide is only as good as the outcome it inspires. These reports are generated by well-renowned publishers on the basis of the data acquired from an extensive research and credible business statistics. Thats why we are proud to provide the widest range of research products, multilingual 24/7 customer support and dedicated custom research services to deliver the insights you need to achieve your goals. Take a look at few of our aspects that makes Beathan Report an asset to your business.

Read the rest here:
Newborn and Prenatal Genetic Testing Market to Make Great Impact in near Future by 2027 - KYT24

Recommendation and review posted by Bethany Smith

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study led by scientists and clinicians from the Institute for Human Genetics and the Benioff Childrens Hospital at the University of California, San Francisco (UCSF) that evaluated the ability of Bionanos optical genome mapping technology and another genome analysis method to diagnose children with genetic conditions who previously went undiagnosed by the standard of care methods alone. Of the 50 children in the study, the optical genome mapping results were sufficient to definitively diagnose 6 patients (or 12%) and, for another 10 patients (or 20%), the Bionano data revealed candidate pathogenic variants. Upon further analysis, it is expected that an additional 3 patients could be diagnosed with the Bionano data, bringing the total of definitively diagnosed patients to 9 (or 18%).

Erik Holmlin, Ph.D., CEO of Bionano Genomics commented, Increasing the number of patients who receive a definitive molecular diagnosis is the driving force behind much of the development of new diagnostic technologies. Every major change in medical guidelines connected to introducing novel methods has been driven by the ability of new methods to diagnose more patients than the previously existing standard of care. This study by the UCSF team shows that Bionanos optical genome mapping can potentially bring another such leap to the clinic by diagnosing many more patients than what existing chromosomal microarray (CMA) and whole exome sequencing (WES) can. Several studies released this year have shown that Saphyr can detect all clinically relevant variants identified by karyotyping, microarray and FISH in both leukemias and genetic disease cases. This UCSF study now shows in the largest cohort analyzed to date that Bionanos optical genome mapping diagnoses more patients than the traditional methods. We believe the increase in diagnosis over conventional methods can be a significant factor in Saphyr gaining widespread adoption as a clinical tool for genetic disease diagnosis and next-generation cytogenomics.

As described in the publication, the UCSF team performed full genome analysis by combining optical genome mapping with Bionano technology and linked-read sequencing on 50 undiagnosed patients with a variety of rare genetic diseases and their parents to determine if this full genome analysis method could help solve cases that had not been diagnosed with previous testing. Of the 50 cases, 42 were previously analyzed by CMA, the first tier medical test for genetic disease cases, and 23 had previously been analyzed with commercial trio whole exome sequencing, and no pathogenic or likely pathogenic variants were identified by these methods.

Bionanos optical genome mapping technology identified a number of pathogenic variants unidentified by CMA and undetectable by WES, including duplications and deletions that were too small to be identified by CMA, or occurred in regions of the genome not typically covered by CMA or WES. Of the additional 7 patients with variations considered to be candidates for pathogenic variants, the findings included deletions, duplications, and inversions. Before concluding that these variants are sufficient to diagnose the patients, further analysis is required since these variants had not previously been reported in patients with similar disease.

The publication is available at: https://www.medrxiv.org/content/10.1101/2020.10.22.20216531v1A recording of the webinar is available at: https://bionanogenomics.com/webinars/optical-mapping-in-rare-genetic-disease-diagnosis/

About Bionano GenomicsBionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionanos Saphyr system is a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools, and genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visitwww.bionanogenomics.com or http://www.lineagen.com.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as may, will, expect, plan, anticipate, estimate, intend and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the contribution of Bionanos technology to the diagnosis of more genetic disease patients when compared to traditional standard of care methods; the capabilities of Bionanos technology in comparison to other genome analysis technologies; our expectations regarding the adoption of Saphyr as a clinical tool for genetic disease diagnosis and next-generation cytogenomics; and Bionanos strategic plans. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive products; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; the loss of key members of management and our commercial team; and the risks and uncertainties associated withour business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2019 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTSCompany Contact:Erik Holmlin, CEOBionano Genomics, Inc.+1 (858) 888-7610eholmlin@bionanogenomics.com

Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLC+1 (617) 430-7577arr@lifesciadvisors.com

Media Contact:Darren Opland, PhDLifeSci Communications+1 (617) 733-7668darren@lifescicomms.com

See more here:
Largest Study To-Date Focused on Undiagnosed Genetic Disease Patients Reveals That Bionano's Optical Genome Mapping Technology Can Diagnose...

Recommendation and review posted by Bethany Smith

Using Your Cancer's Genes to Plan Treatment

When youre first diagnosed with non-Hodgkin lymphoma, your doctor will need to learn more about your tumor. Tests done on a sample of the cancer removed during a biopsy can reveal how your cancer is likely to behave whether it will grow quickly or slowly.

We do extensive molecular and genetic testing to identify certain genetic markers that can predict a high-risk behavior of the tumor, specifically gene rearrangements, Dr. Suchitra Sundaram, medical oncologist at Roswell Park Cancer Center, tells SurvivorNet.

What your doctor learns through these tests can help predict what treatments are likely to work most effectively against your cancer, and what your outcome could be.

Your biopsy sample will go to a laboratory, where a specialist called a pathologist will evaluate its size, shape, and other characteristics under a microscope including its genetic makeup. A few tests look at the cancer cells chromosomes the threads that carry the cells genetic information:

Normally, cells have 23 pairs of chromosomes. Lymphoma cells have changes in their chromosomes for example, too few or too many chromosomes, or areas where genes swap places on chromosomes. These changes can help your doctor learn what type of lymphoma you have, and how it is likely to behave.

Depending upon the number of adverse gene rearrangements identified, some of these patients can be classified into double-hit or triple-hit lymphoma, Dr. Sundaram explains.

Double-hit lymphoma is a type of lymphoma in which there are switches in two genes: MYC or BCL2. Triple-hit lymphoma has changes in three genes: MYC, BCL2, and BCL6. These genes help to control cell growth and death. Changes to them can help the cancer cells survive.

Both double- and triple-hit lymphomas are similar to diffuse large B-cell lymphoma or Burkitt lymphoma. Theyre more aggressive cancers, and people who have them typically have worse overall survival as compared to patients without these gene rearrangements, Dr. Sundaram says.

These lymphomas are more likely to start in people over age 60. They cause swollen lymph nodes, as well as whats known as B symptoms fevers, night sweats, and unexplained weight loss.

Because these cancers are so aggressive, often people are diagnosed when their cancer is already at a late stage. In a small percentage of people with double- and triple-hit lymphoma, the cancer spreads to the brain and spinal cord.

Finding gene swaps is crucial for treatment planning, because some of these patients with double-hit or triple-hit lymphoma may not have the same response to standard chemoimmunotherapy approaches compared to patients without these gene rearrangements, Dr. Sundaram tells SurvivorNet.

Double- and triple-hit lymphomas can be hard to treat. Because they are pretty rare and they havent been well-studied, there is no standard combination of chemotherapy and immunotherapy used to treat them. And, these cancers are more likely to relapse after treatment than more common types of B-cell lymphoma.

Dr. Sundaram says its important for people with double-hit and triple-hit lymphoma to enroll in clinical trials of new drugs combined with chemotherapy and immunotherapy. Taking part in one of these studies could give you access to a new treatment or combination of treatments thats not yet available to the public, and which might work better against your cancer.

Ask the doctor who treats your lymphoma if an appropriate clinical trial is available in your area. If not, your doctor may give you the standard combination of chemotherapy and the monoclonal antibody drug, rituximab (Rituxan), known as R-CHOP. Or, you could get a more intensive combination of chemotherapy and immunotherapy drugs. Your doctor might also prescribe treatment to prevent the cancer from spreading to your brain and spinal cord.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Suchitra Sundaram is a medical oncologist at Roswell Park Cancer Center in Buffalo, New York, as well as an assistant professor of medicine. Her specialties include non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Read More

We do extensive molecular and genetic testing to identify certain genetic markers that can predict a high-risk behavior of the tumor, specifically gene rearrangements, Dr. Suchitra Sundaram, medical oncologist at Roswell Park Cancer Center, tells SurvivorNet.

Your biopsy sample will go to a laboratory, where a specialist called a pathologist will evaluate its size, shape, and other characteristics under a microscope including its genetic makeup. A few tests look at the cancer cells chromosomes the threads that carry the cells genetic information:

Normally, cells have 23 pairs of chromosomes. Lymphoma cells have changes in their chromosomes for example, too few or too many chromosomes, or areas where genes swap places on chromosomes. These changes can help your doctor learn what type of lymphoma you have, and how it is likely to behave.

Depending upon the number of adverse gene rearrangements identified, some of these patients can be classified into double-hit or triple-hit lymphoma, Dr. Sundaram explains.

Double-hit lymphoma is a type of lymphoma in which there are switches in two genes: MYC or BCL2. Triple-hit lymphoma has changes in three genes: MYC, BCL2, and BCL6. These genes help to control cell growth and death. Changes to them can help the cancer cells survive.

Both double- and triple-hit lymphomas are similar to diffuse large B-cell lymphoma or Burkitt lymphoma. Theyre more aggressive cancers, and people who have them typically have worse overall survival as compared to patients without these gene rearrangements, Dr. Sundaram says.

These lymphomas are more likely to start in people over age 60. They cause swollen lymph nodes, as well as whats known as B symptoms fevers, night sweats, and unexplained weight loss.

Because these cancers are so aggressive, often people are diagnosed when their cancer is already at a late stage. In a small percentage of people with double- and triple-hit lymphoma, the cancer spreads to the brain and spinal cord.

Finding gene swaps is crucial for treatment planning, because some of these patients with double-hit or triple-hit lymphoma may not have the same response to standard chemoimmunotherapy approaches compared to patients without these gene rearrangements, Dr. Sundaram tells SurvivorNet.

Double- and triple-hit lymphomas can be hard to treat. Because they are pretty rare and they havent been well-studied, there is no standard combination of chemotherapy and immunotherapy used to treat them. And, these cancers are more likely to relapse after treatment than more common types of B-cell lymphoma.

Dr. Sundaram says its important for people with double-hit and triple-hit lymphoma to enroll in clinical trials of new drugs combined with chemotherapy and immunotherapy. Taking part in one of these studies could give you access to a new treatment or combination of treatments thats not yet available to the public, and which might work better against your cancer.

Ask the doctor who treats your lymphoma if an appropriate clinical trial is available in your area. If not, your doctor may give you the standard combination of chemotherapy and the monoclonal antibody drug, rituximab (Rituxan), known as R-CHOP. Or, you could get a more intensive combination of chemotherapy and immunotherapy drugs. Your doctor might also prescribe treatment to prevent the cancer from spreading to your brain and spinal cord.

Learn more about SurvivorNet's rigorous medical review process.

Dr. Suchitra Sundaram is a medical oncologist at Roswell Park Cancer Center in Buffalo, New York, as well as an assistant professor of medicine. Her specialties include non-Hodgkin lymphoma, Hodgkin lymphoma, chronic lymphocytic leukemia, and multiple myeloma. Read More

Read the rest here:
Double-Hit and Triple-Hit Lymphoma: How Do They Affect Treatment? - SurvivorNet

Recommendation and review posted by Bethany Smith

Preimplantation Genetic Testing Market Size And Forecast

A comprehensive overview of the Preimplantation Genetic Testing Market is recently added by Market Research Intellect to its humongous database. Furthermore, the Preimplantation Genetic Testing Market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. Furthermore, this innovative report makes use of SWOT, PESTLE, and Porters Five Forces analyses to get a closer outlook on the Preimplantation Genetic Testing Market. Furthermore, the Preimplantation Genetic Testing Market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the Preimplantation Genetic Testing Market at the global and regional levels. The study covers the impact of various drivers and manacles on the Preimplantation Genetic Testing Market growth opportunities over the forecast period.

Impact of Covid-19 :

During the first quarter of 2020, different global economies were badly impacted by a viral outbreak of COVID-19. This viral outbreak of the Covid-19 was later recognized as a global pandemic by the World Health Organization (WHO). COVID-19 spread in different global countries, affecting a large number of people in a short timeframe. The outburst of COVID-19 adversely hit different global economies in the world. The stringent regulations imposed by several governments, including complete lockdown and quarantine methodologies to fight against COVID-19, resulted in a massive impact on various business sectors. We at Market Research Intellect offer an informative report on the Preimplantation Genetic Testing Market which helps in making strategic decisions over the forecast period.

Competitive Landscape:

The degree of competition among leading global companies has been elaborated by examining various leading key players operating across the global regions An expert team of research analysts sheds light on various attributes such as -global market competition, market share, latest industry developments, innovative product launches, partnerships, mergers or acquisitions by leading companies in the Preimplantation Genetic Testing Market. The leading manufacturers have been analyzed by using research methodologies for getting insight views on global competition.

Following key players have been profiled with the help of proven research methodologies:

The Preimplantation Genetic Testing Market has been examined into different global market segments such as type, applications and global geographies. Each and every global market segment has been studied to get informative insights into various global regions.

Preimplantation Genetic Testing Market Segmentation:

Preimplantation Genetic Testing Market Segment by Type:

Preimplantation Genetic Testing Market Segment by Application:

Preimplantation Genetic Testing Market Segment by Global Presence:

North America Latin America Middle East Asia-Pacific Africa Europe

The report has been aggregated by using a couple of research methodologies such as primary and secondary research techniques. It helps in collecting informative pieces of professional information for deriving effective insights into the market. This informative report helps in making well informed and strategic decisions throughout the forecast period.

Key questions answered through this analytical market research report include:

What are the latest trends, new patterns and technological advancements in the Preimplantation Genetic Testing Market? Which factors are influencing the Preimplantation Genetic Testing Market over the forecast period? What are the global challenges, threats and risks in the Preimplantation Genetic Testing Market? Which factors are propelling and restraining the Preimplantation Genetic Testing Market? What are the demanding global regions of the Preimplantation Genetic Testing Market? What will be the global market size over the coming future? What are the different effective business strategies followed by global companies?

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Visit link:
Preimplantation Genetic Testing Market with Future Prospects, Key Player SWOT Analysis and Forecast To 2027 - TechnoWeekly

Recommendation and review posted by Bethany Smith

Global Preimplantation Genetic Testing Market: An Overview

The preimplantation genetic testing is an increasingly go-to option for identifying genetic birth effects in children. The technique relies on the use of vitro fertilization before pregnancy. The technique is highly recommended in clinical practices especially in cases wherein both parents have a genetic defect. The tests are performed on an embryo to determine various genetic associations or factors. The PGD or preimplantation genetic diagnosis is the medium to avail this test.

Read Report Overview https://www.transparencymarketresearch.com/preimplantation-genetic-testing-market.html

On the other hand, PGS or presumed genetic screening refers to techniques are applied for the screening of genetically sound parents. The technique is used to screen aneuploidy. The growing demand for genetically testing and rising knowledge of genetics, thanks to big data and AI technology is a promising driver for growth of the preimplantation genetic testing market.

Preimplantation Genetic Testing Market: Notable Developments

In 2018, twin girls in China were conceived using embryos that were specifically designed with the method of gene altering. In 2019, a 74 year Indian women gave birth to first-time twins. It is estimated that nearly 12% of the overall couples are infertile. Additionally, thanks to rising financial stress, and compatibility issues, women tend to conceive a far later in lifecycle. The growth of couples opting for reproductive technologies in Denmark stands at near 7% of all couples. The new technologies made available due to preimplantation genetic testing is expected to witness robust future as economies of scale drive down costs.

Request for Analysis of COVID-19 Impact on Preimplantation Genetic Testing Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=70167

HelpCureHD, an organization has helped 24 families with Huntingtons disease to conceive healthy. The family-supported organization paid for the treatment of 24 families who were diagnosed with huntingtons disease. This is important to take note of as reproduction remains a key family concern and is likely to drive growth from charities. However, the costs of preimplantation genetic testing remain high and pose a major barrier to growth.

Preimplantation Genetic Testing Market: Drivers and Restraints

The rising advent of medical knowledge and growth of technologically advanced genetic devices are expected to result in considerable growth for the preimplantation genetic testing market. Additionally, positive response from several regulatory authorities to genetic testing and possible opportunities for conceving healthier children are expected to be major opportunities. Additionally, more tech companies are also expected to invest in testing.

Recently, Facebook announced its desire to pay women more to conceive later as many women opted out of their jobs to take care of their families. The growing need for women to seek a balance between family and career, and growing tendency towards opting for family are expected to drive investment from the tech sector wherein salaries are extremely high and replacing labor can be far more costly.

Pre Book Preimplantation Genetic Testing Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=70167&ltype=S

Preimplantation Genetic Testing Market: Geographical Analysis

The preimplantation genetic testing market is expected to witness major growth in North America region. The growing choice of women towards conceiving later, growing reliance on technology to identify pre-birth conditions, and expected cutting down costs due to scales of economy are expected to drive major growth in region. Additionally, the preimplantation genetic testing market is expected to drive considerable growth in Asia Pacific region. The region is home to a rising disposable income, and growing access to healthcare. Additionally, large investment in big data and Artificial Intelligence technology by countries like Japan and China are expected to remain major drivers for growth.

More Trending Reports by Transparency Market Research

Serological Testing Market: https://www.biospace.com/article/serological-testing-market-hepatitis-segment-is-anticipated-to-expand-at-the-highest-cagr-during-the-forecast-period/

Disposable Oxygen Masks Market: https://www.biospace.com/article/disposable-oxygen-masks-market-ault-disposable-oxygen-masks-segment-to-offer-attractive-opportunities/

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 State Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

Read more:
Preimplantation Genetic Testing Market Report Analysis With Industry Share Published by Leading Research Firm - TechnoWeekly

Recommendation and review posted by Bethany Smith

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Alopecia market.

Trusted Business Insights presents an updated and Latest Study on Alopecia Market 2020-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Alopecia market during the forecast period (2020-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Alopecia Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19

Report Overview: Alopecia Market

The global alopecia market size was valued at USD 1.5 billion in 2020 and is expected to expand at a CAGR of 8.4% over the forecast period 2021-2027. Rising prevalence of androgenetic alopecia and alopecia areata diseases is the key factor driving market growth.

Lifestyle alterations, such as immoderate intake of tobacco and alcohol, and escalating stress indices are considered as strong triggers for the disease. Though the exact disease cause remains unknown, the genetic factors have been linked to several cases. Moreover, the rise in disposable incomes as well as building emphasis on aesthetics are poised to drive the market demand and product penetration for alopecia.

Aging and hormonal anomalies have been listed as potent causative agents for alopecia. Furthermore, gender plays a key role in disease susceptibility. According to the American Hair Loss Association, it was stated that over 95% of loss of hair in men is caused due to androgenetic alopecia. In addition, a steady increase in consumer awareness toward alopecia therapeutic options are likely to positively impact the market in the future.

Moreover, the rising prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism across the globe, is expected to augment the revenue growth over the forecast period.

Continuous development of new therapeutic strategies is anticipated to boost growth through the projection period. Emergence of rapid-action JAK inhibitors and hair growth stimulation through PRP treatment and pluripotent stem cells are propelling the market growth. The upcoming launch of some breakthrough products indicates a favorable future for the global market.

Disease Type Insights: Alopecia Market

Based on disease types, the market is categorized into androgenetic, areata, cicatricial, totalis, universalis, traction, and others. Between the types, alopecia areata lead the segment in 2019, capturing almost 30% of total market share. The segment growth is supported by a high disease prevalence worldwide and increasing consumer awareness. The disorder is most prevalent in people suffering from autoimmune diseases, namely Downs syndrome, diabetes, and hyperthyroidism. Alopecia areata can progress into alopecia universalis and totalis.

Androgenetic alopecia is estimated to exhibit the fastest growth, driven majorly by the anticipated launch of multiple promising pipeline candidates and an escalating incidence rate. Androgens spawn the condition in people with a genetic disposition to alopecia. Various treatment strategies such as licensed oral, topical, and surgical therapies are accessible for androgenetic alopecia.

End-use Insights: Alopecia Market

Dermatology clinics generated the maximum revenue among all the end-use segments in 2019 and are forecasted to exhibit a lucrative growth rate over the next few years. Increasing number of transplantation and restoration surgeries, coupled with the widespread application of prescription medicines, is expected to contribute significantly to the market position of dermatology clinics.

Homecare settings are powered by broadening penetration of laser treatment and a rise in regulatory sanctions of home-use products. Furthermore, advanced technology, increasing emphasis on convenience, patient compliance, and market presence of contemporary products such as helmets, laser combs, and laser caps are projected to fuel the homecare segment growth.

Key FDA-sanctioned home-use products include Theradome hair grow helmet by Theradome, Inc., iRestore laser hair growth system by Freedom Laser Therapy, Inc., and Hair Max Advanced Laser Comb & HairMax Laser Band 82 by Lexington International.Sales Channel Insights

Based on sales channel, the market is bifurcated into prescription and OTC products. In 2019, prescription products lead the segment and are expected to expand at a significant CAGR over the forecast period. Finasteride and corticosteroids are a few majorly prescribed products for alopecia.Increasing demand for cost-effective treatment, easy accessibility of therapies, and addressing adverse effects associated with approved medications are fueling the requirement for OTC medicines. In addition, an upsurge in the quantity of FDA-licensed OTC products for alopecia is another growth-booster.Gender InsightsAlopecia is less prominent in women than in men. According to the U.S. National Library of Medicine and the American Hair Loss Association, nearly 50% of men experience some grade of hair fall by 50 years of age. Androgen is a leading cause of androgenetic alopecia in men. Moreover, expanding geriatric population base and increasing intake of tobacco are some of the additional factors poised to augment the alopecia market growth.

Female hair-loss occurs irrespective of age; however, almost 40% of women tend to suffer from hair loss by 50 years of age. Female alopecia is driven by an alarming rise in PCOS incidence rates, escalating number of cosmetic practices, and harmful lifestyle patterns. An increase in health consciousness among women is expected to increase the market growth.

Regional Insights: Alopecia Market

Key regional markets include North America, Asia Pacific, Europe, Latin America, and Middle East and Africa (MEA). North America contributed more than 34.0% market share in 2019. Enlarging disease prevalence, technological advancements, novel product development, and increasing disposable income are few contributors to North Americas market share.Asia Pacific region is positioned to exhibit the fastest growth over the next few years. Large population base and rising consumer awareness toward available treatment options are the key factors driving regional growth. Economic betterment and increased per capita healthcare spending, in developing countries such as India, China, and Singapore are expected to create strong commercial opportunities.Alopecia Market Share InsightsSome of the major companies operating in the market include

Rising R&D activities to improve treatment options, accelerated regulatory approvals, and strategic business initiatives undertaken by the key players sum up the major competitive approaches paving the road for expansion. For instance, Johnson & Johnson Services, Inc. launched a public health initiative at the global level to provide comprehensive health solutions in Africa, in April 2016.This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2027. Trusted Business Insights has segmented the global alopecia market report on the basis of disease type, end use, sales channel, gender, and region:

Disease Type Outlook (Revenue, USD Million, 2015 2027)

End-use Outlook (Revenue, USD Million, 2015 2027)

Sales Channel Outlook (Revenue, USD Million, 2015 2027)

Gender Outlook (Revenue, USD Million, 2015 2027)

Looking for more? Check out our repository for all available reports on Alopecia in related sectors.

Quick Read Table of Contents of this Report @ Alopecia Market 2020 and Forecast 2021-2027 Includes Business Impact Analysis of COVID-19

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Originally posted here:
Alopecia Market Analysis, COVID-19 Impact,Outlook, Opportunities, Size, Share Forecast and Supply Demand 2021-2027|Trusted Business Insights - KYT24

Recommendation and review posted by Bethany Smith

Male Hypogonadism Therapy Market Size And Forecast

A comprehensive overview of the Male Hypogonadism Therapy Market is recently added by Market Research Intellect to its humongous database. Furthermore, the Male Hypogonadism Therapy Market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. Furthermore, this innovative report makes use of SWOT, PESTLE, and Porters Five Forces analyses to get a closer outlook on the Male Hypogonadism Therapy Market. Furthermore, the Male Hypogonadism Therapy Market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the Male Hypogonadism Therapy Market at the global and regional levels. The study covers the impact of various drivers and manacles on the Male Hypogonadism Therapy Market growth opportunities over the forecast period.

Impact of Covid-19 :

During the first quarter of 2020, different global economies were badly impacted by a viral outbreak of COVID-19. This viral outbreak of the Covid-19 was later recognized as a global pandemic by the World Health Organization (WHO). COVID-19 spread in different global countries, affecting a large number of people in a short timeframe. The outburst of COVID-19 adversely hit different global economies in the world. The stringent regulations imposed by several governments, including complete lockdown and quarantine methodologies to fight against COVID-19, resulted in a massive impact on various business sectors. We at Market Research Intellect offer an informative report on the Male Hypogonadism Therapy Market which helps in making strategic decisions over the forecast period.

Competitive Landscape:

The degree of competition among leading global companies has been elaborated by examining various leading key players operating across the global regions An expert team of research analysts sheds light on various attributes such as -global market competition, market share, latest industry developments, innovative product launches, partnerships, mergers or acquisitions by leading companies in the Male Hypogonadism Therapy Market. The leading manufacturers have been analyzed by using research methodologies for getting insight views on global competition.

Following key players have been profiled with the help of proven research methodologies:

The Male Hypogonadism Therapy Market has been examined into different global market segments such as type, applications and global geographies. Each and every global market segment has been studied to get informative insights into various global regions.

Male Hypogonadism Therapy Market Segmentation:

Male Hypogonadism Therapy Market Segment by Type:

Male Hypogonadism Therapy Market Segment by Application:

Male Hypogonadism Therapy Market Segment by Global Presence:

North America Latin America Middle East Asia-Pacific Africa Europe

The report has been aggregated by using a couple of research methodologies such as primary and secondary research techniques. It helps in collecting informative pieces of professional information for deriving effective insights into the market. This informative report helps in making well informed and strategic decisions throughout the forecast period.

Key questions answered through this analytical market research report include:

What are the latest trends, new patterns and technological advancements in the Male Hypogonadism Therapy Market? Which factors are influencing the Male Hypogonadism Therapy Market over the forecast period? What are the global challenges, threats and risks in the Male Hypogonadism Therapy Market? Which factors are propelling and restraining the Male Hypogonadism Therapy Market? What are the demanding global regions of the Male Hypogonadism Therapy Market? What will be the global market size over the coming future? What are the different effective business strategies followed by global companies?

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

The rest is here:
Male Hypogonadism Therapy Market Forecast to 2027: Top Companies, Trends & Growth Factors and Trend Forecast to 2027 - TechnoWeekly

Recommendation and review posted by Bethany Smith

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

According to Persistence Market Researchs new report, globalmale hypogonadism marketis slated to exhibit a steady expansion throughout the forecast period (2017-2026). Revenues from the global market for male hypogonadism are estimated to exceed US$ 3,300 Mn by 2026-end.

Governments Taking Initiatives to Spread Awareness about Male Hypogonadism Therapeutics

Lack of sex hormones, usually referred to as male hypogonadism has resulted into many health risks that include osteoporosis, heart disease, and cardiovascular diseases on the back of thinning of bones. Global male hypogonadism market comprises several patented brands that currently have high market penetration. Proliferation in geriatric population in tandem with rising incidences related to rheumatoid arthritis and obesity have been primary factors affecting prevalence of male hypogonadism globally.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/22303

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/22303

Mounting incidences of testosterone deficiency in male population is a key factor that prevalence of male hypogonadism has surged worldwide. Several governments around the world have been taking initiatives to spread the awareness on hypogonadism treatment procedures, for example testosterone replacement therapy (TST), in order to relieve the painful burden on patients and their families.

As low testosterone levels are increasingly associated with exacerbation of chronic conditions, it further results into disorders apropos to hypothalamic-pituitary-gonadal axis. Advent of TST has however enabled reduction in cases of male hypogonadism considerably. With growing awareness related to its treatment among patients, the market is likely to gain an uptick during the forecast period.

Rising availability of the selective androgen receptor modulators (SARMs) has further sustained the market expansion. The development and high availability of SARMs has led toward the provision of improved treatment procedure to patients having androgen deficiencies, thereby influencing the market growth.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/22303

North America will continue to Dominate Global Male Hypogonadism Market

North America will continue to dominate the global male hypogonadism market, with more than one-third revenue share during the forecast period. In addition, revenues from the male hypogonadism market in North America will exhibit the fastest expansion through 2026, as compared to those from all the other regional segments comprised in the report. Europe and Asia-Pacific excluding Japan (APEJ) are also expected to remain lucrative for the male hypogonadism market. The market in APEJ will ride on a slightly higher CAGR than that in Europe through 2026.

Topical gels are expected to remain the most lucrative among drugs available for treatment of male hypogonadism globally, with sales projected to register the fastest expansion through 2026. Injectables will also remain a major revenue contributor to the market. Sales of injectable and transdermal patches are poised to reflect an equal CAGR through 2026.

Testosterone Replacement Therapy to Remain Preferred among Patients

Based on therapy, testosterone replacement therapy is expected to remain preferred among patients with male hypogonadism worldwide. Roughly 66% revenue share of the market is expected to be held by revenues from testosterone replacement therapy by 2026-end. Revenues from gonadotropin replacement therapy will remain slightly more than half revenues gained from testosterone replacement therapy throughout the forecast period.

Klinefelters syndrome is expected to remain the most prevalent disease type observed in the male hypogonadism market, and revenues from treatment of this disease will exceed US$ 1,800 Mn by 2026-end. Kallmann Syndrome and Pituitary Adenomas among disease types will also account for major revenue shares of the market by 2026-end.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

Here is the original post:
The Male Hypogonadism Market To Slither Amidst Covid-19, To Pick Up Pace Post-Covid-19, Reach US$ 3300 Mn - The Think Curiouser

Recommendation and review posted by Bethany Smith

Global hypogonadism drug marketis rising gradually with a substantial CAGR in the forecast period of 2019-2026. Growing number hypogonadism population and robust product pipeline are the key drivers for market growth.

Get Exclusive Sample Copy Of This Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hypogonadism-drug-market

Few of the major competitors currently working in the global hypogonadism drug market areAbbVie Inc., ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly and Company, Clarus Therapeutics, Endo Pharmaceuticals Inc, Merck & Co., Inc., Ferring B.V., Richter Gedeon Vegyeszeti Gyar Nyrt, IBSA Institut Biochimque SA, Laboratoires Genevrier., Teva Pharmaceutical Industries Ltd, Lipocine Inc., Antares Pharma, Pfizer Inc., Aytu BioScience, Inc., Diurnal, HYUNDAIPHARM. Co Ltd., Perrigo Company plc, Bio-Techne and many others.

Report Scope

Market Drivers

Increase in prevalence rate of hypogonadism worldwide acts as a driver for the marketIncrease in the rate of research and development initiatives is driving the marketRising awareness about hypogonadism therapy and technological advancement is driving the market growthOngoing clinical trials is being carried out by many pharmaceuticals companies which acts as a driver for the market

Market Restraints

Effective treatment is either unavailable or unaffordablePatent expiry of major drugs and introduction of generic drugs of branded version is expected to restrain the growth if the marketInadequate knowledge about hypogonadism in some developing countries

TOC of Hypogonadism drug Market Report Contains:

Get Full Table Of content @https://www.databridgemarketresearch.com/toc/?dbmr=global-hypogonadism-drug-market

Segmentation: Global Hypogonadism Drug Market

By Type

Hypergonadotropic HypogonadismHypogonadotropic Hypogonadism

By Therapy Type

Testosterone Replacement TherapySteroid Replacement Therapy

By Treatment

MedicationHormone therapySurgery

By Mechanism of Action Type

Steroidal androgensTestosteroneMethyltestosteroneGonadotropinsChorionic GonadotropinFollicle Stimulating Hormone

By Route of administration

OralInjectableTopical

By End Users

HospitalsHomecareSpecialty ClinicsOthers

By Geography

North AmericaSouth AmericaEuropeAsia-PacificMiddle East & Africa

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hypogonadism-drug-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:[emailprotected]

See the original post here:
Global Hypogonadism Drug Market Business Share, Industry Size and Future Investment Opportunities by 2026||ALLERGAN, AstraZeneca, Bayer AG., Eli Lilly...

Recommendation and review posted by Bethany Smith

Live Conference Call and Webcast at 4:30 PM ET

ENGLEWOOD, CO / ACCESSWIRE / November 5, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, announced today that the Company will present its operational results for the fiscal first quarter ended September 30, 2020 on November 12, 2020, at 4:30 p.m. ET. The Company will review accomplishments from the quarter and provide an overview of its business and growth strategy.

Conference Call Information

888-506-0062 (toll-free) Participant Entry Code - 318202973-528-0011 (international) Participant Entry Code - 318202

The webcast will be accessible live and archived at the following link https://www.webcaster4.com/Webcast/Page/2142/38489 and on Aytu BioScience's website, within the Investors section under Events & Presentations, at aytubio.com, for 90 days.

A replay of the call will be available for fourteen days. Access the replay by calling 1-877-481-4010 (toll-free) or 919-882-2331 (international) and using the replay access code 38489.

About Aytu BioScience, Inc.

Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs. The company currently markets a portfolio of prescription products addressing large primary care and pediatric markets. The primary care portfolio includes (i) Natesto, the only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), (ii) ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and (iii) Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes (i) Cefaclor, a second-generation cephalosporin antibiotic suspension; (ii) Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions; and (iii) Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various for infants and children with fluoride deficiency. Aytu also distributes a COVID-19 IgG/IgM rapid antibody test. This assay is used in the rapid, qualitative diagnostic assessment of the 2019 Novel Coronavirus. Additionally, Aytu recently licensed worldwide rights to develop the Healight technology platform. Healight is an investigational medical device being studied as a prospective treatment for COVID-19 and other respiratory infections.

Aytu also operates a consumer health subsidiary, Innovus Pharmaceuticals, Inc. ("Innovus"), a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men's and women's health and vitality. Innovus commercializes over thirty-five consumer health products competing in large healthcare categories including diabetes, men's health, sexual wellness and respiratory health. The Innovus product portfolio is commercialized through direct-to-consumer marketing channels utilizing the company's proprietary Beyond Human marketing and sales platform.

Aytu's strategy is to continue building its portfolio of revenue-generating Rx and consumer health products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. For more information visit aytubio.com and visit innovuspharma.com to learn about the company's consumer healthcare products.

Forward-Looking Statement

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as ''may,'' ''will,'' ''should,'' ''forecast,'' ''could,'' ''expect,'' ''suggest,'' ''believe,'' ''estimate,'' ''continue,'' ''anticipate,'' ''intend,'' ''plan,'' or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: the regulatory and commercial risks associated with introducing the COVID-19 rapid tests, the accuracy of the COVID-19 rapid tests as compared to other COVID-19 tests, market acceptance of the tests, the ability to obtain FDA approval or authorization for the tests, our ability to obtain sufficient tests to meet consumer demand, if any, the manufacturers' ability to scale up manufacturing to meet customer demand, if any, reputation risks if the tests are not as effective as anticipated, and that the current regulatory environment continues to permit the sale of the tests. We also refer you to the risks described in ''Risk Factors'' in Part I, Item 1A of the company's Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.

Contact for Media and Investors:

James CarbonaraHayden IR(646) 755-7412james@haydenir.com

SOURCE: Aytu BioScience, Inc.

View source version on accesswire.com: https://www.accesswire.com/614510/Aytu-BioScience-to-Report-First-Quarter-Fiscal-2021-Results-and-Provide-Business-Update-on-Thursday-November-12-2020

Follow this link:
Aytu BioScience to Report First Quarter Fiscal 2021 Results and Provide Business Update on Thursday, November 12, 2020 - Press Release - Digital...

Recommendation and review posted by Bethany Smith

The globalHormone Replacement Therapymarket research report offers all the vital data in the domain. The latest report assists new bees as well as established market participants to analyze and predict the Hormone Replacement Therapy market at the regional as well as global level. It covers the volume [k MT] as well as revenues [USD Million] of the global Hormone Replacement Therapy market for the estimated period. Numerous key players Pfizer, Abbott Laboratories, Novo Nordisk, Mylan Laboratories, Eli Lilly, Novartis, Roche, Bayer Healthcare, Merck Serono, Genentech are dominating the global Hormone Replacement Therapy market. These players hold the majority of share of the global Hormone Replacement Therapy market.

Sample of global Hormone Replacement Therapy Market Report at::https://www.marketresearchstore.com/report/global-hormone-replacement-therapy-market-report-2020-industry-757683#RequestSample

The data presented in the global Hormone Replacement Therapy market offers budding opportunities, which help users to make strategic moves and prosper their business. The report highlights the impact of numerous factors that might result in obstructing or propelling the Hormone Replacement Therapy market at global as well as local level. The global Hormone Replacement Therapy market research report offers the summary of key players dominating the market including several aspects such as their financial summary, business strategy, and most recent developments in these firms.

Key points of the global Hormone Replacement Therapy market

Theoretical analysis of the global Hormone Replacement Therapy market stimulators, products, and other vital facets Recent, historical, and future trends in terms of revenue and market dynamics are reported Pin-point analysis of the competitive market dynamics and investment structure is predicted to grow Future market trends, latest innovations, and various business strategies are reported Market dynamics include growth influencers, opportunities, threats, challenges, and other crucial facets

The global Hormone Replacement Therapy market research report offers users with an all-inclusive package of market analysis that includes current market size, expansion rate, and value chain analysis. The global Hormone Replacement Therapy market is segmented on a regional basis Europe, North America, Latin America, Asia Pacific, and Middle East & Africa as well. To offer a comprehensive view and competitive outlook of the global Hormone Replacement Therapy market, our review team employs numerous methodological procedures, for instance, Porters five forces analysis.

Ask Any Kind of Query Before Purchasing the Report Here::https://www.marketresearchstore.com/report/global-hormone-replacement-therapy-market-report-2020-industry-757683#InquiryForBuying

This research report includes the analysis of various Hormone Replacement Therapy market segments {Human Growth Hormone Therapies, Estrogen, Testosterone, Thyroid Hormones}; {Menopause, Male Hypogonadism, Hypothyroidism, Growth Hormone Deficiency, Others}. The bifurcation of the global market is done based on its present and prospective inclinations. The regional bifurcation involves the present market scenario in the region along with the future projection of the global Hormone Replacement Therapy market. The global market report offers an overview of expected market conditions due to changes in the technological, topographical, and economic elements.

Questions answered in the report include

1. What is the expected market size by the end of the forecast period?2. What are the major factors initiating the global Hormone Replacement Therapy market growth?3. What are the latest developments and trending market strategies that are influencing the growth of the Hormone Replacement Therapy market?4. What are the key outcomes of the Hormone Replacement Therapy market developments?5. Who are the key players in the market?6. What are the opportunities and challenges faced by the key players?

Read Detailed Index of full Research Study at:https://www.marketresearchstore.com/report/global-hormone-replacement-therapy-market-report-2020-industry-757683

Key Reasons for Purchasing Global Hormone Replacement Therapy Market Report

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities

See the original post here:
Global Hormone Replacement Therapy Market Recent Trends, Development, Growth and Forecast 2020-2027 - Eurowire

Recommendation and review posted by Bethany Smith

When Jack Hogan was 2, his parents noticed that he would walk into walls at night. Twice he even fell down stairs, says his mother, Jeanette Hogan.

She would tell him to pick up his toys, "And he wouldn't pick them up. And I'd be like, 'It's right there!' And he wouldn't see it."

Jack was ultimately diagnosed with a form of vision impairment that comes from lacking a gene that's key to how the retina, at the back of the eye, senses light. It gave him night blindness and left him lacking peripheral vision.

Now, at age 13, he has undergone surgery to try to improve his vision by fixing his genes. The procedure is an important medical first, and not just for blindness, says his Massachusetts Eye and Ear surgeon, Dr. Jason Comander.

"This is the first time that an FDA-approved gene therapy was given to a patient for any inherited disease," he says.

The gene therapy, called Luxturna, had been tried on more than two dozen patients in clinical trials, Comander says, and it improved most patients' vision either a little or a lot.

But Jack's surgery, after the FDA's approval last December, marks Luxturna's entry into the medical mainstream including insurance coverage for its very hefty price tag: $425,000 for the eye that was operated on Tuesday, and just as much for the second eye, which is scheduled for next week.

Gene therapy works by packaging the needed genetic correction with a harmless virus that can deliver it into the patient's cells.

"The surgery had a very simple goal, which was to take three drops of liquid with this virus in it and put it underneath Jack's retina," Comander says.

The surgery itself was plenty complex, though it involved removing some gel and membranes in the eye. Then, Comander says, "through a tiny little cannula, the tip of which is the size of a human hair, we inject these three drops of liquid underneath the retina. And inside that drop of liquid are many billions of copies of this virus. And the job of the virus is, it's very good at injecting DNA into cells."

Jack, normally active and athletic, had to lie on his back for six hours after the surgery Tuesday. But by Wednesday morning, he was up to introducing himself to reporters: "Hi, my name is Jack Hogan, and I'm 13 years old, and I live in Fair Haven, New Jersey. I like to play sports, basketball well I can't play baseball..."

It's expected to take up to a month to see what effects the surgery has on his vision. Jack says he can't see a difference yet, but he has high hopes: "I hope it will increase my daylight so I could see at night for longer," he says. "And peripheral vision, so I could play basketball, I could see a whole court."

An estimated 1,000 to 2,000 Americans have the type of genetic blindness that Luxturna treats. Dr. Comander says he has several patients who are good candidates.

"It's every eye doctor's dream to take someone who has bad vision and give them the chance of getting better," he says.

But the significance of Jack's operation is far broader, Comander says. The advent of successful, FDA-approved gene therapy for patients like Jack has boosted gene therapy in general a field that crashed in 1999 after a young patient in a clinical trial died. It has been revived by the many researchers who devoted their work to getting it right, Comander says, and now it holds promise for treating many diseases.

"Different forms of inherited retinal disease are the ones that are near and dear to my heart and are also moving through clinical trials," he says. "On a broader note, people are working on hemophilia and other diseases as well."

The high costs of gene therapy treatments like Luxturna do remain a major concern. And for Jack Hogan, there's one other, much smaller downside: His mother says that better vision will mean that he should be able to do more household chores.

For a far more detailed description of Jack Hogan's treatment, STAT describes it at length here.

See the article here:
Medical Milestone In Boston: 13-Year-Old Gets New Gene ...

Recommendation and review posted by Bethany Smith

Employing a strategy known as population modification, which involves using a CRISPR-Cas9 gene drive system to introduce genes preventing parasite transmission into mosquito chromosomes, University of California researchers have made a major advance in the use of genetic technologies to control the transmission of malaria parasites.

University of California, Irvine postdoctoral researcher Adriana Adolfi, in collaboration with colleagues at UC Irvine, UC Berkeley and UC San Diego, followed up on the groups pioneering effort to develop CRISPR-based gene drive systems for making mosquito vectors resistant to transmitting malaria parasites by increasing gene drive effectiveness in female mosquito progeny.

This work mitigates a big issue with the first gene drive systems, which is the accumulation of drive-resistant mosquitoes that could still transmit malaria parasites, said UC Irvine vector biologist Anthony James, the Donald Bren Professor of Microbiology & Molecular Genetics and Molecular Biology & Biochemistry, who was a co-primary investigator on the study.

The second-generation gene drive system described in this paper can be applied to any of the several thousand genes that are essential for insects tosurviveor reproduce, said UC San Diego Distinguished Professor Ethan Bier, a co-author of the study and science director at theTata Institute for Genetics and Society. While it was developed in fruit flies, this system is readily transportable to a broad selection of insect species that serve as vectors for devastating disorders such as Chagas disease, sleeping disease, leishmaniasis andarboviraldiseases.

Study resultsappear inNature Communications. Theydescribe a highly efficient second-generation version of the teams original gene drive, developed for the Indo-Pakistani malaria vector mosquitoAnopheles stephensi. The 2015 work, published inProceedings of the National Academy of Sciences,wasthe first demonstration of a CRISPR-based gene drive in mosquitoes.

In that first study, the gene drive was transmitted to about 99 percent of progeny when the parent in which the gene drive was inserted was a male but only 60 to 70 percent of offspring when the parent in which the gene drive was inserted was a female. A significant number of drive-resistant chromosomes are generated in females; this, in principle, could allow those females to continue to transmit parasites.

Adolfi, lead author of the new study, and collaborators solved the failure to drive efficiently through females by equipping the gene drive with a functional copy of the target gene into which the drive is inserted. Normal function of this target gene is required in this mosquito species for female survival and fertility after she feeds on blood, and its functionality is usually disrupted when the drive system is inserted into the gene.

The resulting female mosquitoes showed strong and consistent drive in a population cage study and negligible production of drive-resistant chromosomes. This strategy of inserting a gene drive into a gene essential for viability or fertility and at the same time including a functional gene that rescues the loss of viability or fertility provides a general solution to drive resistance through females. Also, as with a catalytic converter removing combustion pollution from automobiles, the new system efficiently eliminates genetic errors made in the drive process.

This gene drive system in combination with genes for blocking parasite transmission can now be used to design field-ready strains of mosquitoes. Thorough testing is required to demonstrate safety and efficacy before advancing to field testing.

Nijole Jasinskiene, Hsu-Feng Lee, Arunachalam Ramaiah, J.J. Emerson and Kristy Hwang of UC Irvine; Valentino Gantz, Gerard Terradas and Emily Bulger of UC San Diego; and Jared Bennett and John Marshall of UC Berkeley also participated in the study, which resulted from collaborations between the UC IrvineMalaria Initiative and the UC San Diego Tata Institute for Genetics and Society.

Research support was provided by the Tata Institute for Genetics and Society, the UC Irvine Malaria Initiative,the National Institutes of Health (AI29746,DP5OD023098 andGM123303)and the DARPA Safe Genes program (HR0011-17-2-0047).

Continued here:
UC researchers pioneer more effective method of blocking malaria transmission in mosquitoes - University of California

Recommendation and review posted by Bethany Smith

Mahutte NG, Arici A. Failed fertilization: is it predictable? Curr Opin Obstet Gynecol. 2003;15(3):2118.

Article Google Scholar

Esfandiari N, Javed MH, Gotlieb L, Casper RF. Complete failed fertilization after intracytoplasmic sperm injectionanalysis of 10 years data. Int J Fertil Womens Med. 2005;50(4):18792.

Google Scholar

Vanden Meerschaut F, Nikiforaki D, Heindryckx B, De Sutter P. Assisted oocyte activation following ICSI fertilization failure. Reprod Biomed Online. 2014;28(5):56071.

Article Google Scholar

Escoffier J, Lee HC, Yassine S, Zouari R, Martinez G, Karaouzene T, Coutton C, Kherraf ZE, Halouani L, Triki C, et al. Homozygous mutation of PLCZ1 leads to defective human oocyte activation and infertility that is not rescued by the WW-binding protein PAWP. Hum Mol Genet. 2016;25(5):87891.

CAS Article Google Scholar

Alazami AM, Awad SM, Coskun S, Al-Hassan S, Hijazi H, Abdulwahab FM, Poizat C, Alkuraya FS. TLE6 mutation causes the earliest known human embryonic lethality. Genome Biol. 2015;16:240.

Article Google Scholar

Sang Q, Li B, Kuang Y, Wang X, Zhang Z, Chen B, Wu L, Lyu Q, Fu Y, Yan Z, et al. Homozygous mutations in WEE2 cause fertilization failure and female infertility. Am J Hum Genet. 2018;102(4):64957.

CAS Article Google Scholar

Nakanishi M, Ando H, Watanabe N, Kitamura K, Ito K, Okayama H, Miyamoto T, Agui T, Sasaki M. Identification and characterization of human Wee1B, a new member of the Wee1 family of Cdk-inhibitory kinases. Genes Cells. 2000;5(10):83947.

CAS Article Google Scholar

Han SJ, Chen R, Paronetto MP, Conti M. Wee1B is an oocyte-specific kinase involved in the control of meiotic arrest in the mouse. Curr Biol. 2005;15(18):16706.

CAS Article Google Scholar

Oh JS, Susor A, Conti M. Protein tyrosine kinase Wee1B is essential for metaphase II exit in mouse oocytes. Science. 2011;332(6028):4625.

CAS Article Google Scholar

Yang X, Shu L, Cai L, Sun X, Cui Y, Liu J. Homozygous missense mutation Arg207Cys in the WEE2 gene causes female infertility and fertilization failure. J Assist Reprod Genet. 2019;36(5):96571.

Article Google Scholar

Zhang Z, Mu J, Zhao J, Zhou Z, Chen B, Wu L, Yan Z, Wang W, Zhao L, Dong J, et al. Novel mutations in WEE2: expanding the spectrum of mutations responsible for human fertilization failure. Clin Genet. 2019;95(4):5204.

CAS Article Google Scholar

Zhao S, Chen T, Yu M, Bian Y, Cao Y, Ning Y, Su S, Zhang J, Zhao S. Novel WEE2 gene variants identified in patients with fertilization failure and female infertility. Fertil Steril. 2019;111(3):51926.

CAS Article Google Scholar

Zhou X, Zhu L, Hou M, Wu Y, Li Z, Wang J, Liu Z, Zhang D, Jin L, Zhang X. Novel compound heterozygous mutations in WEE2 causes female infertility and fertilization failure. J Assist Reprod Genet. 2019;36(9):195762.

Article Google Scholar

Dai J, Zheng W, Dai C, Guo J, Lu C, Gong F, Li Y, Zhou Q, Lu G, Lin G. New biallelic mutations in WEE2: expanding the spectrum of mutations that cause fertilization failure or poor fertilization. Fertil Steril. 2019;111(3):5108.

CAS Article Google Scholar

Zhu JY, Cuellar RA, Berndt N, Lee HE, Olesen SH, Martin MP, Jensen JT, Georg GI, Schonbrunn E. Structural basis of wee kinases functionality and inactivation by diverse small molecule inhibitors. J Med Chem. 2017;60(18):786375.

CAS Article Google Scholar

Oh JS, Han SJ, Conti M. Wee1B, Myt1, and Cdc25 function in distinct compartments of the mouse oocyte to control meiotic resumption. J Cell Biol. 2010;188(2):199207.

CAS Article Google Scholar

Sanders JR, Swann K. Molecular triggers of egg activation at fertilization in mammals. Reproduction. 2016;152(2):R41-50.

CAS Article Google Scholar

See the article here:
Novel compound heterozygous mutation in WEE2 is associated with fertilization failure: case report of an infertile woman and literature review - BMC...

Recommendation and review posted by Bethany Smith

One researcher is in Texas. One is in Nebraska. Together, they are striving to launch the hybridized wheat industry.

Lush green plots of hybridized wheat are dotted with people walking through them

Hybridization is the cross breeding of two genetically different varieties or species. And much like what has been accomplished in cotton and corn, hybridizing wheat is expected to improve the crops strength and health and ability to feed a rapidly growing population.

Amir Ibrahim, Ph.D., Texas A&M AgriLife Research wheat breeder in Texas A&Ms Department of Soil and Crop Sciences, Bryan-College Station, has spent the past seven years studying the hybridization of wheat in a partnership with Stephen Baenziger, Ph.D., University of Nebraska-Lincoln small grains breeder.

Ibrahim and Baenziger jointly have tested more than 600 lines of hybrid wheat varieties in Nebraska and Texas, and are now developing the necessary knowledge base, germplasm and enhanced trait pools or patterns from these lines to support the development of hybridized wheat.

Plant breeding partnerships grant

The teams newest project, Plant breeding partnerships: Continuing to develop and validate the tools for hybrid wheat, is supported by a $650,000 U.S. Department of Agriculture National Institute of Food and Agriculture grant.

Together our project team has made great strides toward developing tools to foster hybrid wheat development to maximize wheat yield potential, Baenziger said. This project is expected to help create the scientific and germplasm foundations for successfully launching a U.S. hybrid wheat industry.

Using an integrated approach involving in-house germplasm, chemical hybridizing agents, breeding, phenotyping, genomic selection and quantitative trait loci mapping, the collaborations objectives are to:

Validate increased function from previously made and predicted wheat hybrids in replicated trials.

Continue male and female parent line evaluation for characteristics needed to develop experimental and commercial wheat hybrids in a cost-efficient manner.

Develop those groups showing enhanced traits or patterns and test multiple mating designs for wheat hybrids.

Continue cytoplasmic male sterility line development and identify and validate restorer genes for wheat hybrids.

Ibrahim explained hybrid crops have increased vigor over the two parents in yield and other traits. In hybrids, the female parent does not produce viable pollen, but is used as a seed plant. The male parent has the role of pollinator. Together they have the capacity to combine and express hybrid vigor.

For wheat, past conventional breeding efforts increased hybrid vigor about 10%, but Ibrahim said they want to raise that figure to 15%-20% to make it attractive to producers.

We believe hybrid wheat, which is more climate resilient than pure-line wheat, can contribute to achieving this goal, he said.

Also participating in this latest project are Vikas Belamkar, Ph.D., University of Nebraska geneticist and plant breeder; Bhoja Basnet, Ph.D., International Maize and Wheat Improvement Center, or CIMMYT, hybrid wheat breeder, El Batan, Mexico; and Jochen Reif, Ph.D., Leibniz Institute of Plant Genetics and Crop Plant Science department head, Gatersleben, Germany.

The science needed for cost-effective adoption

Anil Adhikari, Ph.D., a Texas A&M doctoral student who is now at the University of Wisconsin, said for commercial success of hybrid wheat, a cost-effective hybrid seed production method is required. Adhikari worked extensively with Ibrahim on the genetic side of hybridization.

Hybrid seed production based on cytoplasmic male sterility is only feasible if the male lines have fertility-restoring genes, Adhikari said. These genes override the cytoplasmic male sterility in the hybrid seed and make the seeds fertile.

In his study, fertility-restoring genes in a promising restoration source were mapped using linkage mapping approach in a population of 300 recombinant inbred lines. Three consistent major quantitative trait loci, or QTLs,were mapped explaining 18%-40% phenotypic variance. KASP markers were developed using flanking markers of these QTLs.

The KASP markers from this study can be used for characterizing fertility-restoring gene sources and transferring them to male parents in the hybrid breeding program. In addition, the identified candidate genes can serve as a guide to fine map and clone these fertility-restoring genes.

To meet population and food projections, the improvement in wheat productivity needs to be between 1.4% and 1.6% per year. Currently, the productivity increase is about 1% or less.

The researchers say we now have effective chemical hybridizing agents to make experimental hybrids, have identified lines with good traits to facilitate cross-pollination, genomic tools for predicting hybrid vigor, statistical approaches for better estimates of hybrid yield in large experiments, and genomic tools for better use of cytoplasmic male sterile systems.

Hybrid wheat appears to be more stable than conventional wheat under stresses, a trait that is growing in importance, Ibrahim said. Also, he knows the research spin-offs from these efforts may have far-reaching improvements for his and other wheat breeders conventional pure-line breeding.

We know hybrid wheat will still take time but based on these tools we have been working with and the results we are seeing, we believe its time has come, Ibrahim said.

More:
Hybridized wheat: 7 years in the making | Crops | hpj.com - High Plains Journal

Recommendation and review posted by Bethany Smith

Archaeologists have discovered the rare burial of a young child who was laid to rest 8,000 years ago without arm and leg bones, a new study finds.

The child, who was no older than 8, was buried on what is now Alor Island, Indonesia. During the burial ceremony, the long bones in the child's arms and legs were removed and disposed elsewhere, and part of the child's face was painted with red ochre, a pigment often used in burials across the ancient world.

"Ochre pigment was applied to the cheeks and forehead and an ochre-colored cobblestone was placed under the child's head when they were buried," study lead researcher Sofia Samper Carro, a lecturer of archaeology at Australian National University in Canberra, said in a statement.

Related: 8,000-year-old heads on stakes found in mysterious underwater grave

This isn't the only burial from this region with missing arm and leg bones. "The lack of long bones is a practice that has been documented in several other burials from a similar time period in Java, Borneo and Flores, but this is the first time we have seen it in a child's burial," Samper Carro said. "We don't know why long bone removal was practiced, but it's likely some aspect of the belief system of the people who lived at this time."

Archaeologists don't know whether the child was male or female, but an analysis of their teeth and skeleton suggests the youngster likely died between the ages of 4 and 8. However, the dental analysis suggests that the child was slightly older (6 to 8 years old), while the skeleton was so small, it looked like it belonged to a 4 to 5 year old, indicating that the child's growth may have been stunted by genetic or environmental factors.

"We want to do some further paleo-health research to find out if this smaller skeleton is related to diet or the environment or possibly to being genetically isolated on an island," Samper Carro said, referring to the idea that some species shrink when they live on an isolated island, such as the extinct dwarf elephants that used to live in Flores.

Granted, ancient adult skulls found on Alor are also small. And if genetics don't explain their short stature, it's possible nutrition played some role, Samper Carro said. "These hunter-gatherers had a mainly marine diet and there is evidence to suggest protein saturation from a single food source can cause symptoms of malnourishment, which affects growth," she said. "However, they could have been eating other terrestrial resources, such as tubers."

Whatever the researchers learn will shed light on this region's cultural practices during the early mid-Holocene epoch, which began at the end of the last ice age about 11,500 years ago. "Child burials are very rare, and this complete burial is the only one from this time period," Carro said.

Child burials become more common in the archaeological record starting about 3,000 years ago, she said. "But, with nothing from the early Holocene period, we just don't know how people of this era treated their dead children. This find will change that."

The study was published online Oct. 28 in the journal Quaternary International.

Originally published on Live Science.

See original here:
Rare ancient burial contains child whose arms and legs were removed - Livescience.com

Recommendation and review posted by Bethany Smith

A recent study published in the Journal of Hypertension indicates that there is a direct association between social ties and risk of hypertension in women. The longitudinal study including more than 28,000 people between the ages of 45 and 85 years found that women with a small social circle and limited social participation (less than two social activities in a month) are more likely to get hypertension than women who had better or more social interactions. Hypertension risk was also found to be higher in widowed women than married women.

Hypertension (high blood pressure) is assumed to be more prevalent in the male population. However, experts suggest that it affects both the genders equally. In fact, after a certain age, women are more prone to the condition than men and the former have several very unique risk factors for high blood pressure both in the pre and post-menopausal age.

Unique risk factors

According to the American Heart Association, high blood pressure is not directly related to gender. However, pregnancy, menopause and use of birth control pills are some unique factors that put women at a higher risk of hypertension.

Research suggests that women who smoke, have a genetic predisposition to hypertension or are overweight are highly likely to have high blood pressure on regular use of birth control pills.

Similarly, pregnant women often experience high blood pressure. If you have had a history of hypertension, you may have to consult your doctor before trying to conceive since high blood pressure can harm both the baby and the mother.

Gestational hypertension develops after 20 weeks of pregnancy; you may develop this type of hypertension even if you never had the condition before. And then there is pre-eclampsia, a pregnancy complication wherein the woman has high blood pressure and limb swelling and protein in urine. Pre-eclampsia can be life-threatening for the mother and preterm delivery is the only way to resolve it.

Finally, after menopause, when the estrogen levels drop, a womans chances of developing hypertension increases significantly. Studies suggest that a combination of various factors including individual genetics, body mass index (BMI) and increased sympathetic nervous system activity are responsible for this spike in risk. The sympathetic nervous system is responsible for the flight and fight response. It increases blood pressure, decreases intestinal motility and accelerates heart rate.

Difference in symptoms

As per the European Society of Cardiology, hypertensive women experience more arterial stiffness, atrial fibrillation and heart failure in older age than hypertensive men. Since they have a smaller diameter of arteries, aneurysms in women rupture at a much smaller size than in men.

Hypertension is said to be a silent killer. Usually, it does not show any symptoms unless there is organ damage. However, in some young and middle-aged women, the condition can also be symptomatic. Such women report some of the following symptoms:

A lot of these symptoms are associated with stress or menopause. Experts suggest that if you notice these symptoms, it is best to consult a doctor, especially if you have a family history of hypertension.

For more information, read our article on High blood pressure.

Health articles on News18 are written by myUpchar.com, Indias first and biggest resource for verified medical information. At myUpchar, researchers and journalists work with doctors to bring you information on all things health.

Read the original here:
Hypertension in Women: How the Symptoms and Risk Factors Vary - News18

Recommendation and review posted by Bethany Smith

GAITHERSBURG, Md., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the three and nine months ended September 30, 2020 and updated its full year 2020 guidance.

Over the last 22 years, Emergent has built a solid business founded on demonstrable strengths in partnering, manufacturing, and integrating value-added M&A, said Robert G. Kramer, president and chief executive officer of Emergent BioSolutions. The strength of our core business and the accelerated growth of our contract development and manufacturing unit validate our strategy to pursue leadership positions across the public health threat market. Our diverse product and service portfolio gives us continued confidence in executing our strategy, delivering on our commitments to our partners and customers, and creating value for our shareholders.

FINANCIAL HIGHLIGHTS (unaudited)

(in millions)

Q3 2020

Q3 2019

$ Change

% Change

Total Revenues

$385.2

$311.8

$73.4

24%

Net Income

$39.5

$43.2

($3.7)

(9)%

Adjusted Net Income (1)

$119.0

$64.8

$54.2

84%

Adjusted EBITDA (1)

$168.1

$106.4

$61.7

58%

(in millions)

YTD 2020

YTD 2019

$ Change

% Change

Total Revenues

$972.4

$745.7

$226.7

30%

Net Income

$119.7

$7.6

$112.1

*

Adjusted Net Income (1)

$225.1

$69.6

$155.5

*

Adjusted EBITDA (1)

$339.5

$145.4

$194.1

*

* % change is greater than 100%

SELECT Q3 2020 BUSINESS ACCOMPLISHMENTS

Completed an offering of $450 million in aggregate principal amount 3.875% Senior Unsecured Notes due in 2028. The Company utilized the proceeds from the offering to repay $353 million outstanding under its revolving credit facility with the remainder to be utilized for general corporate purposes.

Announced the initiation of a Phase 3 clinical trial sponsored by the National Institutes of Health to evaluate the safety, tolerability, and efficacy of hyperimmune globulin products, including the Company's COVID-19 Human Immune Globulin (COVID-HIG), as a potential treatment in adult patients hospitalized with COVID-19.

Announced U.S. Food and Drug Administration (FDA) approval of the shelf life extension of NARCAN (naloxone HCl) Nasal Spray from 24 months to 36 months.

Secured approximately $60 million in new business and existing project extensions across development services, drug substance manufacturing, and drug product manufacturing towards the Company's contract development and manufacturing (CDMO) portfolio.

2020 FINANCIAL PERFORMANCE (unaudited)

Story continues

(I) Quarter Ended September 30, 2020 (Q3)

Revenues

Total Revenues

For Q3 2020, total revenues were $385.2 million, an increase of $73.4 million as compared to 2019. Total revenues reflect an increase in contract development and manufacturing services revenues partially offset by a decrease in product sales and contracts and grants revenues.

Product Sales

For Q3 2020, product sales were $202.2 million, a decrease of $54.0 million or 21% as compared to 2019. Other product sales increased due to increased sales of BAT[Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] and VIGIV [Vaccinia Immune Globulin Intravenous (Human)] offset by a decline in sales of travel health vaccines.

(in millions)

Three Months Ended September 30,

2020

2019

% Change

Product Sales

NARCAN Nasal Spray

$88.8

$75.0

18%

Anthrax vaccines

$73.9

$40.3

83%

ACAM2000

$1.0

$112.1

(99)%

Other

$38.5

$28.8

34%

Total Product Sales

$202.2

$256.2

(21)%

Contract Development and Manufacturing (CDMO) Services

For Q3 2020, revenue from the Companys contract development and manufacturing operations was $157.1 million, an increase of $137.1 million as compared to 2019. The increase is largely due to the contribution of arrangements across development, drug substance manufacturing, and drug product manufacturing services with industry and government customers.

Contracts and Grants

For Q3 2020, revenue from the Companys development-based contracts and grants was $25.9 million, a decrease of $9.7 million as compared to 2019. The decrease primarily reflects the completion of development activities associated with the AV7909 product candidate in 2019, partially offset by recent new development awards related to the Company's COVID-19 product candidates.

Operating Expenses

Cost of Product Sales and Contract Development and Manufacturing (CDMO) Services

For Q3 2020, cost of product sales and contract development and manufacturing services was $149.0 million, an increase of $41.0 million or 38% as compared to 2019. The increase is primarily due to a charge of $29.9 million associated with contingent consideration liabilities due to the increased expectation that the Company will meet its final sales milestone for NARCAN Nasal Spray, a charge of $13.8 million related to a write-down of inventory balances due to the expected expiration of a portion of the Company's travel health vaccines, and an increase in volume in CDMO services offset by a decline in volume of product sales.

Read the original here:
Emergent BioSolutions Reports Financial Results for Third Quarter and Nine Months Ended September 30, 2020 and Updates Full Year 2020 Guidance - Yahoo...

Recommendation and review posted by Bethany Smith

Dublin, Nov. 05, 2020 (GLOBE NEWSWIRE) -- The "In-Space Manufacturing, Servicing, and Transportation Market - A Global Market and Regional Analysis: Focus on End User, Operation and Country Analysis - Analysis and Forecast, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

The in-space manufacturing, servicing, and transportation industry analysis projects the market to grow at a significant CAGR of 17.26% on the basis of value during the forecast period from 2020 to 2030. North America is expected to dominate the market in 2030 with a share of 45.57%. The North America region includes the U.S. and Canada. The U.S. is expected to acquire a major share in 2030 due to the increase in the investment and strategic developments of companies in the country.

The technological development and feasibility of on-orbit servicing, repair, inspection, and assembly have already been witnessed in the past decades. There are several factors that are contributing to the significant growth of in-orbit manufacturing, servicing, and transportation market. Some of these factors include focused efforts by emerging space companies to develop on-orbit space capabilities, increasing efforts toward space debris removal, and increasing satellite launches.

The in-space manufacturing, servicing, and transportation market research provides detailed market information for segmentation such as end-user, operation, and region. The purpose of this market analysis is to examine the in-space manufacturing, servicing, and transportation market outlook in terms of factors driving the market, trends, technological developments, and competitive benchmarking, among others.

The report further takes into consideration the market dynamics and the competitive landscape, along with the detailed financial and product contribution of the key players operating in the market.

While highlighting the key driving and restraining forces for this market, the report also provides a detailed study of the end-users, which include commercial and military & government. The report also analyzes different operations that include manufacturing, servicing, and transportation. Furthermore, the service sub-segment is further segmented into life extension, de-orbiting, satellite repair and inspection, and relocation.

The in-space manufacturing, servicing, and transportation market is segregated by region under four major regions, namely North America, Europe, Asia-Pacific, and Rest-of-the-World. Data for each of these regions (by country) has been provided in the market study.

Key Companies in the Global In-Space Manufacturing, Servicing, and Transportation Industry

The key market players in the global in-space manufacturing, servicing, and transportation market include Airbus S.A.S., Altius Space, Astrobotics, Astroscale, Momentus Space, Atomos Space, Chandah Space Technologies, D-Orbit SpA, Honeybee Robotics, Infinite Orbits, Orbit Fab, Northrop Grumman Corporation, SSL (a Maxar Company), Tethers Unlimited, Inc., and Made In Space, among others.

Key Questions Answered in this Report:

Key Topics Covered:

1 Markets1.1 Industry Outlook1.2 Business Dynamics1.2.1 Business Drivers1.2.1.1 Increasing Developments by Emerging Space Players on On-Orbit Space Capabilities1.2.1.2 Focus on In-situ resource utilization (ISRU) for Sustainable Space Infrastructure1.2.1.3 Increased Benefits for Space Missions Through the Adoption of On-Orbit Services1.2.2 Business Challenges1.2.2.1 Technical Challenges Hindering the Potential of On-Orbit Space Capabilities1.2.2.2 Legal and Regulatory Issues1.2.3 Business Strategies1.2.3.1 New Product Development1.2.3.2 Market Developments1.2.4 Corporate Strategies1.2.4.1 Contracts, Agreements, Partnerships, Collaborations, and Acquisitions1.2.5 Business Opportunities1.2.5.1 Increasing Efforts on Space Debris Removal1.2.5.2 Increasing Number of Satellite Launches

2 Application2.1 Demand Analysis of In-Space Manufacturing, Servicing, and Transportation (by End User)2.1.1 Commercial2.1.2 Military and Government

3 Products3.1 Global In-Space Manufacturing, Servicing, and Transportation Market (by Operation)3.2 Demand Analysis of In-Space Manufacturing, Servicing, and Transportation Market (by Operation)3.2.1 Manufacturing3.2.2 Servicing3.2.2.1 Life Extension3.2.2.1.1 Life Extension, By Orbit3.2.2.2 De-Orbiting3.2.2.2.1 De-Orbiting, By Orbit3.2.2.3 Satellite Inspection and Repair3.2.2.3.1 Satellite Inspection and Repair, By Orbit3.2.2.4 Relocation3.2.2.4.1 Relocation, By Orbit3.2.3 Transportation

4 Regions4.1 North America4.2 Europe4.3 Asia-Pacific4.4 Rest-of-the-World

5 Markets - Competitive Benchmarking & Company Profiles5.1 Competitive Benchmarking5.2 Astrobotic Technology, Inc.5.2.1 Company Overview5.2.1.1 Role of Astrobotic Technology, Inc. in In-Space Manufacturing, Servicing, and Transportation Market5.2.2 Corporate Strategies5.2.2.1 Partnerships and Collaborations5.2.2.2 Contracts and Agreements5.2.3 Strength and Weakness of Astrobotic Technology, Inc.5.3 Airbus5.3.1 Company Overview5.3.1.1 Role of Airbus in In-Space Manufacturing, Servicing, and Transportation Market5.3.1.2 Product Portfolio5.3.1.3 Production Sites5.3.2 Corporate Strategies5.3.2.1 Partnerships and Collaborations5.3.2.2 Contracts and Agreements5.3.3 Strength and Weakness of Airbus5.3.4 R&D Analysis5.4 Altius Space Machines Inc.5.4.1 Company Overview5.4.1.1 Role of Altius Space Machines Inc. in In-Space Manufacturing, Servicing, and Transportation Market5.4.1.2 Product Portfolio5.4.2 Corporate Strategies5.4.2.1 Contracts and Agreements5.4.3 Strength and Weakness of Altius Space Machines Inc.5.5 Astroscale5.5.1 Company Overview5.5.1.1 Role of Astroscale in In-Space Manufacturing, Servicing, and Transportation Market5.5.1.2 Product Portfolio5.5.1.3 Production Sites5.5.2 Business Strategies5.5.2.1 Market Developments5.5.3 Corporate Strategies5.5.3.1 Partnerships and Collaborations5.5.3.2 Contract and Agreement5.5.4 Strength and Weakness of Astroscale5.6 Atomos Space5.6.1 Company Overview5.6.1.1 Role of Atomos Space in In-Space Manufacturing, Servicing, and Transportation Market5.6.1.2 Product Portfolio5.6.2 Strength and Weakness of Atomos Space5.7 Chandah Space Technologies5.7.1 Company Overview5.7.1.1 Role of Chandah Space Technologies in In-Space Manufacturing, Servicing, and Transportation Market5.7.2 Strength and Weakness of Chandah Space Technologies5.8 D-Orbit5.8.1 Company Overview5.8.1.1 Role of D-Orbit in In-Space Manufacturing, Servicing, and Transportation Market5.8.1.2 Product Portfolio5.8.2 Business Strategies5.8.2.1 Product Developments5.8.3 Strength and Weakness of D-Orbit5.9 Honeybee Robotics5.9.1 Company Overview5.9.1.1 Role of Honeybee Robotics in In-Space Manufacturing, Servicing, and Transportation Market5.9.1.2 Product Portfolio5.9.1.3 Production Sites5.9.2 Corporate Strategies5.9.2.1 Contracts and Agreements5.9.3 Strength and Weakness of Honeybee Robotics Corporation5.1 Infinite Orbits5.10.1 Company Overview5.10.1.1 Role of Infinite Orbits in In-Space Manufacturing, Servicing, and Transportation Market5.10.1.2 Product Portfolio5.10.2 Strength and Weakness of Infinite Orbits5.11 Orbit Fab5.11.1 Company Overview5.11.1.1 Role of Orbit Fab in In-Space Manufacturing, Servicing, and Transportation Market5.11.1.2 Product Portfolio5.11.2 Corporate Strategies5.11.2.1 Contracts and Agreements5.11.3 Strength and Weakness of Orbit Fab5.12 Northrop Grumman Corporation5.12.1 Company Overview5.12.1.1 Role of Northrop Grumman Corporation in In-Space Manufacturing, Servicing, and Transportation Market5.12.1.2 Product Portfolio5.12.2 Corporate Strategies5.12.2.1 Partnerships and Collaborations5.12.2.2 Contracts and Agreements5.12.3 Strength and Weakness of Northrop Grumman Corporation5.12.4 R&D Analysis5.13 Tethers Unlimited Inc.5.13.1 Company Overview5.13.1.1 Role of Tethers Unlimited Inc. in In-Space Manufacturing, Servicing, and Transportation Market5.13.1.2 Product Portfolio5.13.2 Business Strategies5.13.2.1 Product Developments5.13.3 Corporate Strategies5.13.3.1 Contracts and Agreements5.13.4 Strength and Weakness of Tethers Unlimited Inc.5.14 SSL (Maxar Technologies Company)5.14.1 Company Overview5.14.1.1 Role of SSL (Maxar Technologies Company) in In-Space Manufacturing, Servicing, and Transportation Market5.14.1.2 Product Portfolio5.14.2 Strength and Weakness of SSL (Maxar Technologies Company)5.15 Made In Space5.15.1 Company Overview5.15.1.1 Role of Made In Space in In-Space Manufacturing, Servicing, and Transportation Market5.15.1.2 Product Portfolio5.15.2 Business Strategies5.15.2.1 Product Developments5.15.3 Corporate Strategies5.15.3.1 Contracts and Agreements5.15.4 Strength and Weakness of Made In Space5.16 Momentus Space5.16.1 Company Overview5.16.1.1 Role of Momentus Space in In-Space Manufacturing, Servicing, and Transportation Market5.16.1.2 Product Portfolio5.16.2 Corporate Strategies5.16.2.1 Partnerships and Collaborations5.16.2.2 Contracts and Agreements5.16.3 Strength and Weakness of Momentus Space

6 Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/zdqqr7

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the original post:
Insights on the In-Space Manufacturing, Servicing, and Transportation Global Market to 2030 - Increasing Developments in On-Orbit Space Capabilities...

Recommendation and review posted by Bethany Smith

MJR Power & Automation has successfully completed the life extension project of the trailing suction hopper dredger (TSHD) Heortnesse, owned and operated by PD Ports.

Under the project, MJR delivered the complete electrical power, propulsion, dredging & integrated control, automation & monitoring system upgrade including Lloyds class approval in an aggressive 7 month project schedule from design through to installation and commissioning.

A&P Group awarded MJR the contract in late September 2019 after an extensive competitive tender process against leading global marine companies for thedesign and replacement of the vessels entire diesel electric propulsion, dredging and automation plant.

MJR was contracted to deliver a complete turnkey package including engineering, procurement, installation & commissioning with full design approval by Lloyds Register of Shipping.

The design, engineering and procurement was carried out during the 4th quarter of 2019 followed by the construction, automation and FAT during the early part of 2020 at MJRs HQ in Stockton-on-Tees.

Installation and commissioning teams completed the site works at A&Ps Tees docks, Middlesbrough during March 2020 and April followed by successful trials in May 2020.

Read this article:
MJR completes work on TSHD Heortnesse - Dredging Today

Recommendation and review posted by Bethany Smith

Databridgemarketresearch.com announces the release of the report Global Glucose Tolerance Test Market Size, Share & Trends Analysis Report By 2027. The market data analysed and evaluated in the world class Global Glucose Tolerance Test Market report makes to achieve the business goals and objectives in preset time frame. This market research report endows with productive ideas which in turn help to make the product more effective and striking in the competitive market. This report covers the specific study of the industry which explains what the market definition, classifications, applications, engagements, and global industry trends are. The Global Glucose Tolerance Test Market research report takes into account key product developments and tracks recent acquisitions, mergers and research in the industry by the key market players.

Global Glucose Tolerance Test Market is set to witness a healthy CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. Increasing diabetic cases worldwide is driving the growth of this market.

DOWNLOAD FREE PDF SAMPLE COPY OFREPORT@HTTPS://DATABRIDGEMARKETRESEARCH.COM/REQUEST-A-SAMPLE/?DBMR=GLOBAL-GLUCOSE-TOLERANCE-TEST-MARKET

Global Glucose Tolerance Test Market By Product (Smart Sensors, Blood Glucose Testing Kit, Others), Indication (Reactive Hypoglycemia, Gestational Diabetes, Diabetes, Insulin Resistance,), End-User (Hospitals, Home, Diagnostic Clinics, Others), Geography (South America, North America, Europe, Middle East & Africa, Asia-Pacific) Industry Trends and Forecast to 2026

Competitive Analysis:

Global glucose tolerance test market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of glucose tolerance test market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Major Market Competitors/Players:

Some of the major players operating in the global glucose tolerance test market are Thermo Fisher Scientific Inc., Medtronic, NIPRO, Trividia Health, Inc., Dexcom, Inc., Dorevitch Pathology, Penlan Healthcare Ltd, Quest Diagnostics Incorporated, Johnson & Johnson Services, Inc., Abbott, Laboratory Corporation of America Holdings., ARUP Laboratories., Cleveland HeartLab, Inc., Merck KGaA, Bayer AG, Life Extension, and among others.

Market Definition: Global Glucose Tolerance Test Market

The capability to absorb glucose (Sugar) from our body cells after the consumption of some amount of sugar is measured with the help of glucose tolerance test. This test is used to diagnose diabetes. It has its major application in screening all pregnant women for gestational diabetes, as it can cause further complications during pregnancy. So early detection and prompt treatment are important. Fasting blood sugar levels and haemoglobin A1C values are used by doctors to diagnose type 1 and type 2 diabetes as well as prediabetes.

Market Drivers:

Market Restraints:

Key Development in the Market:

Order a Copy of This ResearchReport @https://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-glucose-tolerance-test-market

Segmentation: Global Glucose Tolerance Test Market

Reasons to Purchase this Report

Customization of the Report

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

Read the original:
Global Glucose Tolerance Test Market 2020 Covid 19 Analysis, Market Size, Market Growth, Competitive Strategies, and Worldwide Demand 2027 - BCFocus

Recommendation and review posted by Bethany Smith

Global Lingonberry Extract Industry: with growing significant CAGR during Forecast 2020-2027

Latest Research Report on Lingonberry Extract Market which covers Market Overview, Future Economic Impact, Competition by Manufacturers, Supply (Production), and Consumption Analysis

Understand the influence of COVID-19 on the Lingonberry Extract Market with our analysts monitoring the situation across the globe. Request Now

The market research report on the global Lingonberry Extract industry provides a comprehensive study of the various techniques and materials used in the production of Lingonberry Extract market products. Starting from industry chain analysis to cost structure analysis, the report analyzes multiple aspects, including the production and end-use segments of the Lingonberry Extract market products. The latest trends in the pharmaceutical industry have been detailed in the report to measure their impact on the production of Lingonberry Extract market products.

Leading key players in the Lingonberry Extract market are Shanghai Freemen, Natrol, Source Naturals, Swanson, Life Extension, Athelas Nutraceuticals, Bio Botanica, Dongling Health Food

Get sample of this report @ https://grandviewreport.com/sample/36564

Product Types:Powder, Granular

By Application/ End-user:Food Industry, Pharmaceuticals Industry, Other

Regional Analysis For Lingonberry Extract Market

North America(the United States, Canada, and Mexico)Europe(Germany, France, UK, Russia, and Italy)Asia-Pacific(China, Japan, Korea, India, and Southeast Asia)South America(Brazil, Argentina, Colombia, etc.)The Middle East and Africa(Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Get Discount on Lingonberry Extract report @ https://grandviewreport.com/discount/36564

This report comes along with an added Excel data-sheet suite taking quantitative data from all numeric forecasts presented in the report.

Research Methodology:The Lingonberry Extract market has been analyzed using an optimum mix of secondary sources and benchmark methodology besides a unique blend of primary insights. The contemporary valuation of the market is an integral part of our market sizing and forecasting methodology. Our industry experts and panel of primary members have helped in compiling appropriate aspects with realistic parametric assessments for a comprehensive study.

Whats in the offering: The report provides in-depth knowledge about the utilization and adoption of Lingonberry Extract Industries in various applications, types, and regions/countries. Furthermore, the key stakeholders can ascertain the major trends, investments, drivers, vertical players initiatives, government pursuits towards the product acceptance in the upcoming years, and insights of commercial products present in the market.

Full Report Link @ https://grandviewreport.com/industry-growth/Lingonberry-Extract-Market-36564

Lastly, the Lingonberry Extract Market study provides essential information about the major challenges that are going to influence market growth. The report additionally provides overall details about the business opportunities to key stakeholders to expand their business and capture revenues in the precise verticals. The report will help the existing or upcoming companies in this market to examine the various aspects of this domain before investing or expanding their business in the Lingonberry Extract market.

Contact Us:Grand View Report(UK) +44-208-133-9198(APAC) +91-73789-80300Email : [emailprotected]

Read more here:
Lingonberry Extract Market: Qualitative analysis of the leading players and competitive industry scenario | Shanghai Freemen, Natrol, Source Naturals,...

Recommendation and review posted by Bethany Smith